Trial Profile
A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Methotrexate; Tacrolimus; Tacrolimus
- Indications Graft-versus-host disease; Multiple myeloma
- Focus Adverse reactions
- 19 Nov 2020 Status changed from active, no longer recruiting to completed.
- 21 May 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Jun 2017 Preliminary results (n=6, enrolled between Sep 2015 to Dec 2016) presented at the 22nd Congress of the European Haematology Association